These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34331826)

  • 1. Challenging patient phenotypes in the management of anaemia of chronic kidney disease.
    Pramod S; Goldfarb DS
    Int J Clin Pract; 2021 Nov; 75(11):e14681. PubMed ID: 34331826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roxadustat in the treatment of anaemia in chronic kidney disease.
    Del Vecchio L; Locatelli F
    Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials.
    Eckardt KU; Agarwal R; Farag YM; Jardine AG; Khawaja Z; Koury MJ; Luo W; Matsushita K; McCullough PA; Parfrey P; Ross G; Sarnak MJ; Vargo D; Winkelmayer WC; Chertow GM
    Nephrol Dial Transplant; 2021 Nov; 36(11):2039-2048. PubMed ID: 33188693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
    Mima A
    Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heme iron polypeptide for the management of anaemia of chronic kidney disease.
    Dull RB; Davis E
    J Clin Pharm Ther; 2015 Aug; 40(4):386-90. PubMed ID: 25953602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current therapeutic approach for anaemia after kidney transplant.
    Nissaisorakarn V; Nissaisorakarn P; Kantachuvesiri S
    Curr Opin Nephrol Hypertens; 2023 Jan; 32(1):35-40. PubMed ID: 36250458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
    Weir MR
    Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics.
    Minutolo R; Locatelli F; Gallieni M; Bonofiglio R; Fuiano G; Oldrizzi L; Conte G; De Nicola L; Mangione F; Esposito P; Dal Canton A;
    Nephrol Dial Transplant; 2013 Dec; 28(12):3035-45. PubMed ID: 24145459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
    Gupta N; Wish JB
    Am J Kidney Dis; 2017 Jun; 69(6):815-826. PubMed ID: 28242135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anemia management in chronic kidney disease and dialysis: a narrative review.
    Collister D; Rigatto C; Tangri N
    Curr Opin Nephrol Hypertens; 2017 May; 26(3):214-218. PubMed ID: 28306566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines.
    Hung SC; Kuo KL; Tarng DC; Hsu CC; Wu MS; Huang TP
    Nephrology (Carlton); 2014 Dec; 19(12):735-9. PubMed ID: 25156587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
    Chen H; Cheng Q; Wang J; Zhao X; Zhu S
    J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutics of managing reduced red cell mass associated with chronic kidney disease - Is there a case for earlier intervention?
    Elliott J
    J Vet Pharmacol Ther; 2023 May; 46(3):145-157. PubMed ID: 37036059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
    Maruno S; Tanaka T; Nangaku M
    Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis.
    Zheng L; Tian J; Liu D; Zhao Y; Fang X; Zhang Y; Liu Y
    Br J Clin Pharmacol; 2022 Mar; 88(3):919-932. PubMed ID: 34428860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current treatment practices for anemia in patients with chronic kidney disease and future opportunities with hypoxia-inducible factor prolyl hydroxylase inhibitors: a narrative review.
    Kile M; Sudchada P
    Int Urol Nephrol; 2021 Feb; 53(2):283-290. PubMed ID: 32770437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance.
    Dasgupta I; Bagnis CI; Floris M; Furuland H; Zurro DG; Gesualdo L; Heirman N; Minutolo R; Pani A; Portolés J; Rosenberger C; Alvarez JES; Torres PU; Vanholder RC; Wanner C;
    Clin Kidney J; 2024 Aug; 17(8):sfae205. PubMed ID: 39135937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation.
    Icardi A; Paoletti E; De Nicola L; Mazzaferro S; Russo R; Cozzolino M
    Nephrol Dial Transplant; 2013 Jul; 28(7):1672-9. PubMed ID: 23468534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.